

REMARKS/ARGUMENTS

Claims 23, 24 and 26-44 are active. Claims 41-44 are withdrawn as indicated.

Claim 23 has been amended to incorporate the limitations of Claim 25 per the indication that Claim 25 is allowable (Action at page 5).

Claims 32, 34 and 38 have been amended to provide “avian keratinocytes.”

Claim 40 is amended to provide that the medicine is prepared by introducing the virion into a pharmaceutically acceptable carrier as described in [0045] of the specification.

Thus, the items noted in the rejection under 35 USC 112, second paragraph (pages 2-3 of the Action) are no longer applicable.

The specification is amended at page 12 to provide the section heading “Brief Description of the Drawings” as required at page 2 of the Action.


The rejection of Claims 23, 24, 26-35 under 35 USC 102(a) in view Vanhoutteghem and the rejection of Claims 23, 24, and 26-28 under 35 USC 103(a) over Samarut and the ATCC catalog is no longer applicable as Claim 25, which was not rejected, has been incorporated into Claim 23. Thus, according to the comments at page 5 of the Action, the claims are patentable over these citations.

An English Translation of the priority document is filed here. A mark-up of the priority document reflecting changes between the original priority application and the text of the PCT is also attached for information purposes.

A Notice of Allowance for all pending claims is requested.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Daniel J. Pereira

Registration No.: 45,518

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 08/07)